Work

Supplementary Figure S1 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC

Year: 2026

Type: supplementary-materials

Abstract: Top row: Squamous cell carcinoma with high pre-treatment total lesion glycolysis (TLG) on FDG PET. Following mid-treatment response and a standard 60Gy (non-boosted) plan, the patient developed locoregional progression (LRP) within 1 year, suggesting high pre-treatment TLG confers elevated LRP risk. They also developed distant metastatic progression (DM) within 1 year, which was correlated with high residual mid-treatment TLG. Bottom row: Adenocarcinoma with relatively low pre-treatment TLG and high residual mid-treatment TLG on FDG PET. A boost plan (74–90Gy) was delivered for non-response and resulted in no LRP event, yet the patient developed distant metastatic progression (DM) within 1 year, suggesting high mid-treatment TLG confers elevated DM risk.

DOI: 10.1158/1078-0432.33252873

Authors: Jing Zeng, Sunan Cui, Daniel S. Hippe, Jie Fu, Faisal Yaseen, Yulun He, John Kang, Clemens Grassberger, Hubert J. Vesselle, Paul E. Kinahan, Keith D. Eaton, Christina S. Baik, Rafael Santana-Davila, Sylvia Lee, Ramesh Rengan, Stephen R. Bowen

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7203500827

Cites:

Cited by:

Related to: 10